// App-Quantinova.ai

TPS6094 : Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.

Researchers

Presenter

  • Jean-Pascal H. Machiels

Principal Investigators

  • Lisa F. Licitra

  • Yungan Tao

  • Chia-Jui Yen

  • Danny Rischin

  • John Waldron

  • Barbara Burtness

  • Vincent Gregoire

  • Sanjiv S. Agarwala

  • Jeffrey Yorio

  • Jean-Pierre Delord

  • Sercan Aksoy

  • Sadakatsu Ikeda

  • Ruey-Long Hong

  • Joy Yang Ge

  • Holly M. Brown

  • Behzad Bidadi

  • Lillian L. Siu

Medical Centers

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

  • Institut Gustave-Roussy, Villejuif, France

  • Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Yale University School of Medicine, New Haven, CT

  • St. Lukes Cancer Center-Anderson, Bethlehem, PA

  • Texas OncologyAustin Central, Austin, TX

  • Institut Claudius Regaud, Toulouse, France

  • Ankara Universitesi Tip Fakultesi, Ankara, Turkey

  • Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • Canada

  • Taiwan

  • Japan

  • Italy

  • Turkey

  • Australia

  • United States

  • France

  • Belgium

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Serpin B3

Drug/Treatment

  • Pembrolizumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03040999

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved